Dr Richard Moss, MD | |
110 Long Pond Rd, Suite 201, Plymouth, MA 02360-2642 | |
(508) 747-1322 | |
(508) 747-6612 |
Full Name | Dr Richard Moss |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 110 Long Pond Rd, Plymouth, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053376228 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 50189 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Richard Moss, MD 110 Long Pond Rd, Suite 201, Plymouth, MA 02360-2642 Ph: () - | Dr Richard Moss, MD 110 Long Pond Rd, Suite 201, Plymouth, MA 02360-2642 Ph: (508) 747-1322 |
News Archive
While Congress and the rest of the nation turn the battle over healthcare reform into a pro-wrestling-style steel cage death match with enough rhetoric to choke an English professor, at least one expert is looking beyond the bills on the table for a different solution.
Nationally known and recognized political analyst David Gergen spoke today at the National Home Care & Hospice Association's March on Washington event about the uncertain times that we face as a country.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to identify disease processes at an early stage and to track responses to treatment.
Lpath, Inc., the industry leader in bioactive lipid-targeted therapeutics, announced today the closing of its previously announced $12.5 million registered direct offering.
Researchers at the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have shown for the first time that it is possible to sustain therapeutic gene expression in the central nervous system for up to a year, even in the presence of an anti-viral immune response mechanism that is normally present in humans.
› Verified 4 days ago